Search clinical trials for: Broadly Neutralizing

Total 150 results

National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
David Ho
US Military HIV Research Program; Henry M. Jackson Foundation for the Advancement... and other collaborators

Recruiting

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

HIV-1-infection

Tanzania
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Acute HIV Infection

United States, Brazil, Peru
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Human Immunodeficiency Virus

United States
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
ImmunityBio, Inc.; Rockefeller University

Recruiting

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

HIV Infection

United States
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

HIV

United States
National Institute of Allergy and Infectious Diseases...
Sanofi; ModeX Therapeutics

Terminated

Pharmacokinetics and Safety of SAR441236

HIV-1-infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults (VRC 611)

HIV

United States
Michael Hoelscher
National Institute for Medical Research - Mbeya Medical Research Centre (NIMR-MMRC) and other collaborators

Active, not recruiting

Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania. (bNAb)

HIV/AIDS

Tanzania
ViiV Healthcare

Completed

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections

United States, Canada, Argentina, Brazil, Mexico, Peru
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial (VRC 603)

HIV-1 Infected Adults With Controlled Viremia

United States
National Institute of Allergy and Infectious Diseases...
Rockefeller University

Withdrawn

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

HIV Infections

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Human Immunodeficiency Virus

United States
International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Dual bNAb Treatment in Children

HIV Infection

Botswana
IrsiCaixa

Withdrawn

Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation (ITATI)

HIV Infection

Spain, Netherlands, Italy
Rockefeller University
Aarhus University Hospital; University Hospital of Cologne

Completed

Romidepsin Plus 3BNC117 Phase 2a Study (ROADMAP)

Human Immunodeficiency Virus (HIV)

Germany, Denmark, United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

3BNC117 and 10-1074 in ART-treated Individuals

Human Immunodeficiency Virus

United States
Aarhus University Hospital
Odense University Hospital; Rigshospitalet, Denmark; Hvidovre University Hospital and other collaborators

Active, not recruiting

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART (eCLEAR)

Hiv

United Kingdom, Denmark
Luis Montaner
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Unknown

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

HIV/AIDS | HIV | HIV-1 Infection

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

HIV-1

United States, Puerto Rico
Rockefeller University

Completed

3BNC117-LS First-in-Human Phase 1 Study

Human Immunodeficiency Virus

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Healthy Adult Immune Response

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Prevention

United States
University of Minnesota

Withdrawn

N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

HIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and Infections

United States
Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Infection | Monoclonal Antibody, Human | HIV Antibodies | VRC01 Monoclonal Antibody | Neutralizing Antibody

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

HIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal Antibody

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Monoclonal Antibody, Human | HIV Antibodies | Neutralizing Antibody | Prevention of HIV Infection

United States
Rockefeller University
University Hospital of Cologne

Completed

3BNC117 and 10-1074 in HIV-infected Individuals

Human Immunodeficiency Virus (HIV)

United States, Germany
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
Washington University School of Medicine

Recruiting

Evaluating the Human Immune Response to the JYNNEOS Vaccine

Virus Diseases | Vaccinia

United States
Indiana University

Recruiting

Combination of Buffered Anesthetic to Treat Mandibular Molars

Symptomatic Irreversible Pulpitis

United States
Sinovac Life Sciences Co., Ltd.

Recruiting

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

COVID-19

China
CSL Behring

Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B

United States, Canada, Israel
The Second Affiliated Hospital of Chongqing Medical...

Recruiting

The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects

SARS-CoV-2 | Prevention

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

Study to Evaluate GR1801's Efficacy and Safety

Rabies Post-exposure Prophylaxis

China
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Rabies Virus Infection

China
Chang Gung Memorial Hospital

Recruiting

Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups

COVID-19

Taiwan
Immorna Biotherapeutics, Inc.
ICON plc

Recruiting

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine

COVID-19 | Infectious Disease

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Epstein-Barr Virus Infection | Infectious Mononucleosis | Herpesvirus

United States
University Hospital, Strasbourg, France

Recruiting

Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS (BKV-Allograf)

BK Virus Infection

France
Chemi-Pharm AS

Recruiting

The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 (Coronavirus Disease-19) Infection in Healthy Volunteer Individuals

SARS CoV 2 Infection

Estonia
Chang Gung Memorial Hospital

Recruiting

(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies

Cancer

Taiwan
Centre Hospitalier Régional d'Orléans

Recruiting

Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies (PNAS)

COVID-19 | SARS CoV 2 Infection

France
Changhai Hospital

Not yet recruiting

Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. (TEST)

Pancreatitis, Chronic

China
ANRS, Emerging Infectious Diseases

Recruiting

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort. (PRECOVIM)

COVID-19 | Immunocompromised Host

France

Search clinical trials for: Broadly Neutralizing

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations